That's a bit of an overstatement - is the data marginal, yes, but is the data better than historical data for the few alternatives that these relapsed/refractory patients have, yes. This trial was a crapshoot by HANA to get the quickest approval possible for Marquibo, because they didn't have the funds to support a larger, controlled pivotal trial. If they get rejected, does that mean Marquibo has no future, no. The pk/pd data on this drug clearly points to an improvement over standard vincristine - i.e. it can be delivered in greater doses, stays in the body longer, and has a similar safety profile as standard vincristine, which is still widely used in the front-line treatment of many blood cancers. So, there is a future for this drug (as well as TLON's other drug, Medadione), regardless of the pending decision. What that means in terms of dilution and potential share price over the next few years, who knows, but it ain't good.